Cipher Pharmaceuticals (CPH) to Release Earnings on Thursday

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) is scheduled to post its quarterly earnings results after the market closes on Thursday, May 9th. Analysts expect Cipher Pharmaceuticals to post earnings of C$0.14 per share for the quarter.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its earnings results on Thursday, March 14th. The company reported C$0.41 earnings per share (EPS) for the quarter, topping the consensus estimate of C$0.15 by C$0.26. Cipher Pharmaceuticals had a return on equity of 28.19% and a net margin of 96.32%. The firm had revenue of C$6.70 million for the quarter, compared to analysts’ expectations of C$7.31 million.

Cipher Pharmaceuticals Price Performance

Cipher Pharmaceuticals stock traded up C$0.10 during midday trading on Tuesday, reaching C$9.40. 15,318 shares of the stock traded hands, compared to its average volume of 38,199. The company has a quick ratio of 2.67, a current ratio of 9.19 and a debt-to-equity ratio of 0.44. Cipher Pharmaceuticals has a 12 month low of C$3.11 and a 12 month high of C$9.98. The stock’s fifty day moving average is C$8.32 and its 200-day moving average is C$6.73. The stock has a market cap of C$226.63 million, a P/E ratio of 8.45 and a beta of 1.04.

Analysts Set New Price Targets

Separately, Citigroup boosted their price objective on shares of Cipher Pharmaceuticals from C$4.75 to C$8.00 and gave the company a “buy” rating in a research report on Wednesday, February 14th.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.